The cost-effectiveness of screening men for Chlamydia trachomatis: a review of the literature.
BACKGROUND
An important consideration in determining whether to implement or continue a program to screen men for chlamydia is its cost-effectiveness. A review of the literature on the cost-effectiveness of screening men for chlamydia could potentially provide guidance.


METHODS
An Ovid Medline search was conducted for articles published between 1990 and July 2007 using terms for cost, chlamydia, and male. This search returned 175 articles; 25 were retained after eliminating those not relevant to cost-effectiveness studies of male chlamydia screening. We added 4 articles that were in-press or are published in this issue, for a total of 29. These articles were examined for common themes and their results summarized.


RESULTS
The reviewed studies examined both proactive and opportunistic screening and included screening of risk groups and of the general population. Some older studies included enzyme immunoassays; more recent studies featured nucleic acid amplification assays. Six studies used dynamic transmission models. Fourteen studies analyzed male and female chlamydia screening interventions. Several contained sufficient data to examine the cost-effectiveness of male screening compared with female screening. Male screening was preferred to expanded female screening in 1 study. In other studies, combined male and female screening programs were cost-saving.


CONCLUSIONS
Studies comparing chlamydia screening in men with chlamydia screening in women may be the most useful for guidance to programs. The studies which compare the 2 generally have found that screening men from the general population is not preferred to screening women from the general population, although 1 study found that screening of men from risk groups can be cost-effective compared with screening women from the general population.
Gift
Thomas L
TL
Centers for Disease Control and Prevention, Division of STD Prevention, Atlanta, Georgia 30333, USA. tgift@cdc.gov
Blake
Diane R
DR
Gaydos
Charlotte A
CA
Marrazzo
Jeanne M
JM
D002690:Chlamydia Infections / Q000175:diagnosis / Q000191:economics* / Q000453:epidemiology / Q000382:microbiology; D002692:Chlamydia trachomatis; D016358:Contact Tracing; D003362:Cost-Benefit Analysis / Q000191:economics; D005260:Female; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000191:economics* / Q000379:methods*; D018803:Models, Economic; D015231:Sexually Transmitted Diseases, Bacterial / Q000175:diagnosis / Q000191:economics* / Q000453:epidemiology / Q000382:microbiology